HDAC3 Inhibitor Compounds for Isoform-Selective Therapeutic Action
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer, inflammation, and neurodegeneration diseases such as Alzheimer's and Huntington's disease, as well as diabetes, lack effective inhibitors targeting histone deacetylase-3 (HDAC3), which are crucial for regulating gene expression and cellular function.
Innovation Solution
Development of compounds of Formula I, which are inhibitors of histone deacetylase-3 (HDAC3), for use in pharmaceutical compositions to treat or prevent these conditions by administering an effective amount of the compounds to a subject.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If HDAC3 inhibitors are developed for treating cancer, inflammation, neurodegeneration diseases and diabetes, then therapeutic efficacy is improved, but currently no effective HDAC3-specific inhibitors are available
Solution Approach 1:
The invention segments the broad HDAC inhibitor class by developing compounds with selective affinity for HDAC3 specifically, rather than inhibiting all HDAC isoforms. This is achieved through specific molecular structures (Formula I compounds) that target the unique features of HDAC3's catalytic domain, enabling isoform-selective inhibition and resolving the lack of HDAC3-specific therapeutics
Solution Approach 2:
The invention applies local quality by designing compounds with specific structural features (substituents at defined positions in Formula I) that confer selective binding to HDAC3. The molecular structure is optimized with particular functional groups and substitution patterns that match HDAC3's active site characteristics, enabling selective inhibition of this specific isoform while sparing others
2Reliability
If HDAC3 inhibition is used to enhance gene expression and treat diseases, then gene expression activation is improved, but off-target effects on other HDAC isoforms may occur
Solution Approach 1:
The invention achieves segmentation of HDAC isoform effects by creating compounds that selectively inhibit only HDAC3. The molecular design (Formula I with specific A, B, and substituent groups) targets HDAC3's unique structural features, thereby activating gene expression programs controlled by HDAC3 without inadvertently affecting other HDAC isoforms that regulate different gene sets
Solution Approach 2:
The invention employs local quality through precise molecular design where specific functional groups and substitution patterns in Formula I compounds create high affinity and selectivity for HDAC3's active site. This localized optimization of molecular structure ensures that only HDAC3 is inhibited, preventing off-target effects on other HDAC isoforms while maintaining potent gene expression activation
Data Source
AI summary
The present invention relates to Compounds of Formula I: and pharmaceutically acceptable salts or prodrug thereof, wherein R1, R2, R3, A and B are as defined herein. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treating or preventing cancer, inflammation, neurodegeneration disease and/or diabetes in a subject.